Filtered By:
Condition: Ischemic Stroke
Drug: Plavix

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 1287 results found since Jan 2013.

Association of CYP2C19 Polymorphisms With Clopidogrel Reactivity and Clinical Outcomes in Chronic Ischemic Stroke.
CONCLUSIONS: Despite associations betweenCYP2C19variants and on-clopidogrel platelet reactivity, there was no significant difference in rates of CVEs in the chronic stroke phase among the 3 clopidogrel-metabolizing groups ofCYP2C19variants. PMID: 31006731 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 18, 2019 Category: Cardiology Authors: Tanaka T, Yamagami H, Ihara M, Miyata T, Miyata S, Hamasaki T, Amano S, Fukuma K, Yamamoto H, Nakagawara J, Furui E, Uchiyama S, Hyun B, Yamamoto Y, Manabe Y, Ito Y, Fukunaga R, Abumiya T, Yasaka M, Kitagawa K, Toyoda K, Nagatsuka K Tags: Circ J Source Type: research

Aspirin plus Clopidogrel versus Aspirin Mono-Therapy for Ischemic Stroke: A Meta-Analysis.
CONCLUSIONS: The addition of clopidogrel to aspirin for patients with TIA or IS appeared to significantly reduce the risk of IS recurrence with a possible increase in the risk of bleeding compared with aspirin alone. PMID: 31112048 [PubMed - as supplied by publisher]
Source: Scandinavian Cardiovascular Journal - May 23, 2019 Category: Cardiology Tags: Scand Cardiovasc J Source Type: research

Monitoring of biological response to clopidogrel after treatment for non-cardioembolic ischemic stroke or transient ischemic attack.
CONCLUSIONS: Platelet function results obtained using different assays for patients having experienced a non-cardioembolic ischemic stroke or TIA were discordant. Transmission electron microscopy could be useful in certain clinical contexts when platelet function assay results disagree. PMID: 31632514 [PubMed]
Source: American Journal of Translational Research - October 23, 2019 Category: Research Tags: Am J Transl Res Source Type: research

Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Reactivity in Patients With Minor Stroke or TIA
Conclusions: Ticagrelor is superior to clopidogrel in inhibiting platelet reactivity measured by the PL platelet function analyzer among patients with acute minor stroke or TIA. Our study confirmed the finding of the main analysis of PRINCE trial in a different assay. Large randomized controlled trials are needed to evaluate our findings.Clinical Trial Registration:Clinicaltrials.gov NCT02506140.
Source: Frontiers in Neurology - June 9, 2020 Category: Neurology Source Type: research

Combined impact of body mass index and glycemic control on the efficacy of clopidogrel-aspirin therapy in patients with minor stroke or transient ischemic attack.
CONCLUSIONS: Compared with aspirin alone, efficacy of clopidogrel-aspirin therapy for stroke still exists in overweight/obesity patients with normal glycemic control. METHODS: In Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial, 3044 patients with available baseline GA were recruited. Low/normal weight and overweight/obesity were defined as BMI < 25 kg/m2 and ≥ 25 kg/m2, respectively. Elevated and low GA levels were defined as GA levels > 15.5 % and ≤ 15.5 %, respectively. The primary outcome was stroke recurrence during the 90-day follow-up. PMID: 32544082 [PubMed ...
Source: Aging - June 15, 2020 Category: Biomedical Science Authors: Chen Z, Mo J, Xu J, Wang A, Qin H, Zheng H, Liu L, Meng X, Li H, Wang Y Tags: Aging (Albany NY) Source Type: research

Left Atrial Appendage Closure for Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation: the LAA-CAA Cohort
AbstractAnticoagulation increases the risk of intracerebral hemorrhage (ICH) in patients with cerebral amyloid angiopathy (CAA), so the management of stroke-risk in patients with both atrial fibrillation (AF) and CAA is controversial. Advances in left atrial appendage closure (LAAC) techniques provide a stroke-risk-reduction option which avoids long-term oral anticoagulation (OAC). We aimed to evaluate the safety of this intervention in patients with CAA. This is an observational cohort study of patients with severe CAA (with or without ICH) and AF who were treated with LAA closure. The Watchman ™ and Amulet® LAAC devic...
Source: Translational Stroke Research - August 6, 2020 Category: Neurology Source Type: research

Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention.
Abstract Effective platelet inhibition is the main goal of the antiplatelet therapy recommended as a standard treatment in the secondary prevention of non-embolic ischemic stroke. Acetylsalicylic acid (aspirin) and clopidogrel are commonly used for this purpose worldwide. A low biological response to antiplatelet agents is a phenomenon that significantly reduces the therapeutic and protective properties of the therapy. The mechanisms leading to high on-treatment platelet reactivity are still unclear and remain multifactorial. The aim of the current review is to establish the background of resistance to antiplatele...
Source: Medicina (Kaunas) - January 10, 2021 Category: Universities & Medical Training Authors: Wiśniewski A Tags: Medicina (Kaunas) Source Type: research

Association between insulin resistance and aspirin or clopidogrel resistance in Chinese patients with recent ischemic stroke/TIA.
Conclusions: Insulin resistance was an independent predictor for development of antiplatelet drug resistance in patients with recent minor ischemic stroke or TIA. More attention should be paid to recognize these patients and antithrombotic effect should be monitored when antiplatelet drugs were applied to these patients. PMID: 33455562 [PubMed - as supplied by publisher]
Source: Neurological Research - January 21, 2021 Category: Neurology Tags: Neurol Res Source Type: research

Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review
The aim of this mini-review is to discuss the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardioembolic ischemic stroke and transient ischemic attacks (TIA). The methodology is based on a literature review of available peer-reviewed English studies listed in PubMed. The findings reveal that aspirin remains a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA. Nevertheless, currently, there are also other agents, i.e., ticagrelor, clopidogrel, and cilostazol, that can be applied. In addition, the results indicate that ti...
Source: Frontiers in Neurology - February 25, 2021 Category: Neurology Source Type: research

Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review
Stroke is one of the world's leading causes of disability and death. Antiplatelet agents are administered to acute ischemic stroke patients as secondary prevention. Clopidogrel involves biotransformation by cytochrome P450 (CYP) enzymes into an active metabolite, and single nucleotide polymorphisms (SNPs) can influence the efficacy of this biotransformation. Despite the therapeutic advantages of aspirin, there is significant inter-individual heterogeneity in response to this antiplatelet drug. In this clinical review, the recent advances in the biomarkers of antiplatelet agents in acute ischemic stroke are discussed. The s...
Source: Frontiers in Neurology - June 10, 2021 Category: Neurology Source Type: research

Impact of Diabetes on Platelet Function in Acute Ischemic Stroke Patients Taking Dual Antiplatelet Therapy
Conclusions: In acute ischemic stroke patients taking DAPT, DM is associated with increased platelet reactivity and higher prevalence of clopidogrel HRPR.
Source: Frontiers in Neurology - November 4, 2021 Category: Neurology Source Type: research

P2Y12 Reaction Units and Clinical Outcomes in Acute Large Artery Atherosclerotic Stroke: A Multicenter Prospective Study
CONCLUSIONS: Acute PRU evaluation possesses predictive value for recurrent ischemic stroke, especially within 7 days in AIS/TIA with LAA.PMID:35249906 | DOI:10.5551/jat.63369
Source: Journal of Atherosclerosis and Thrombosis - March 7, 2022 Category: Cardiology Authors: Kazuki Fukuma Hiroshi Yamagami Masafumi Ihara Tomotaka Tanaka Toshiyuki Miyata Shigeki Miyata Koichi Kokame Kunihiro Nishimura Yuriko Nakaoku Haruko Yamamoto Mikito Hayakawa Kenji Kamiyama Yukiko Enomoto Ryo Itabashi Eisuke Furui Yasuhiro Manabe Masayuki Source Type: research